NASDAQ:AMDA - Amedica Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.59
▼ -0.06 (-3.64%)
Get New Amedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMDA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Amedica in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.59.
N/A
The current consensus among 0 investment analysts is to n/a stock in Amedica. This rating has held steady since April 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason McCarthy at Maxim Group
3/6/2018Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason Kolbert at Maxim Group
1/24/2018Maxim GroupReiterated RatingHoldLow
i
Rating by Jason Kolbert at Maxim Group
11/27/2017LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
i
Rating by Jeffrey Cohen at LADENBURG THALM/SH SH
9/25/2017Maxim GroupDowngradeBuy ➝ HoldLow
i
4/24/2017Maxim GroupReiterated RatingBuy$60.00Low
i
Rating by Jason Kolbert at Maxim Group
11/24/2016Maxim GroupSet Price TargetBuy$60.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/10/2016Maxim GroupInitiated CoverageBuy$60.00N/A
i
(Data available from 4/18/2016 forward)
Amedica logo
SINTX Technologies, Inc. operates as a commercial biomaterial company. It focuses on using silicon nitride technology platform to develop, manufacture and sell a range of medical devices. The firm markets spinal fusion products and develops products for use in total hip and knee joint replacements. Its FDA-cleared and CE-marked spine products are marketed in the U.S. and selected markets in Europe and South America. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in 1996 and is headquartered in Salt Lake City, UT.
Read More

Today's Range

Now: $1.59
$1.54
$1.66

50 Day Range

MA: $0.26
$0.09
$2.19

52 Week Range

Now: $1.59
$0.18
$6.40

Volume

604,023 shs

Average Volume

1,074,342 shs

Market Capitalization

$18.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedica?

The following sell-side analysts have issued reports on Amedica in the last year:
View the latest analyst ratings for AMDA.

What is the current price target for Amedica?

0 Wall Street analysts have set twelve-month price targets for Amedica in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Amedica in the next year.
View the latest price targets for AMDA.

What is the current consensus analyst rating for Amedica?

Amedica currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AMDA.

What other companies compete with Amedica?

How do I contact Amedica's investor relations team?

Amedica's physical mailing address is 1885 WEST 2100 SOUTH, SALT LAKE CITY UT, 84119. The medical equipment provider's listed phone number is (801) 839-3500 and its investor relations email address is [email protected] The official website for Amedica is www.amedica.com.